Caffeine as a probe for CYP1A2 activity: Potential influence of renal factors on urinary phenotypic trait measurements

Pharmacogenetics

Volumn 4, Issue 3, 1994, Pages 117-124

  Tang, B K ^a   Zhou, Y ^a   Kadar, D ^a   Kalow, W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLURIC ACID; 1 METHYLXANTHINE; 1,7 DIMETHYLURIC ACID; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; ANTIBIOTIC AGENT; CAFFEINE; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; IBUPROFEN; ORAL CONTRACEPTIVE AGENT; PARAXANTHINE;

ADULT; ARTICLE; BIOTRANSFORMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADULT; BIOTRANSFORMATION; CAFFEINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MOLECULAR PROBES; OXIDOREDUCTASES; PHENOTYPE; REFERENCE VALUES;

EID: 0028333956     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199406000-00002     Document Type: Article

References (25)

1. Birkett DJ, Miners JO. Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events. Br J Clin Pharmacol 1991: 31. 405-408.
2. Balogh A, Irmisch E, Wolf P, Letrari S, Splinter FK, Hempel E, Klinger G, Hoffmann A. The influence of levonorgestrel, ethynylestradiol and their combination on the metabolism of caffeine and metamizol. Zent bl. Gynakol 1991: 113, 1388-1396.
3. Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther 1982; 32, 98-106.
4. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992: 2, 116-127.
5. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987: 42. 157-165.
6. Denaro CP, Benowitz NL. Caffeine metabolism: Disposition in liver disease and hepatic-function testing. In: Watson RR, ed. Drug and alcohol abuse reviews. Vol. 2: Liver pathology and alcohol. The Humana Press Inc., Totowa, NJ. 1991: 513-539.
7. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983: 33, 591-602.
8. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992: 2. 73-77.
9. Gu L. Caffeine metabolism as index of cytochrome P4501A2 activity. MSc thesis, University of Toronto 1992, 76-77 p.
10. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991: 4. 391-407.
11. Kadlubar FF, Butler MA, Kaderlik KR, Chou HC, Lan NP. Polymorphisms for aromatic amine metabolism in humans: Relevance for human carcinogenesis. Environ Health Persp 1992: 98, 69-74.
12. Kalow W, Tang BK. Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991a: 49. 44-48.
13. Kalow W, Tang BK. Use of caffeine metabolite ratio to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991b: 50, 508-519.
14. Kalow W, Tang BK. The use of caffeine for enzyme assays: A critical appraisal. Clin Pharmacol Ther 1993: 53, 503-514.
15. Lane JD, Steege JF, Rupp SI, Kuhn CM. Menstrual cycle effect on caffeine elimination in the human female. Eur J Clin Pharmacol 1992: 43, 543-546.
16. Lelo A, Miners JO, Robson RA, Birkett DJ. Quantitative assessment of caffeine partial clearance in man. Br J Clin Pharmacol 1986: 22, 183-186.
17. Patwardhan RV, Desmond PV, Johnson RF, Schenker S. Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med 1980: 95, 603-608.
18. Tang BK, Grant DM, Kalow W. Isolation and identification of 5-acetylamino-6-formylamino-3-methyluracil as a major metabolite of caffeine in man. Drug Metab Dispos 1983: 11, 218-220.
19. Tang BK, Zubovits T, Kalow W. Determination of acetylated caffeine metabolites by high-performance exclusion chromatography. J Chromatogr 1986: 375, 170-173.
20. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: Validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991: 49, 648-657.
21. Tang-Liu DD-S, Williams RL, Riegelman S. Disposition of caffeine and its metabolites in man. J Pharmacol Exp Ther 1983: 224, 180-185.
22. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez FJ, Miners JO. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 1992: 2, 173-183.
23. Vistisen K, Loft S, Poulsen HE. Cytochrome P4501A2 activity in man measured by caffeine metabolism: Effect of smoking, broccoli and exercise. Adv Exp Med Bio 1990: 238, 407-411.
24. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992: 13, 1561-1568.
25. Wahllander A, Mohr S, Paumgartner G. Assessment of hepatic function: Comparison of caffeine clearance in serum and saliva during the day and at night. J Hepatol 1990: 10, 129-137